Skip to main content
ARROWHEAD PHARMACEUTICALS, INC. logo

ARROWHEAD PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · ARWR ISIN · US04280A1007 LEI · 549300O3CSB8T7OZ3D66 US Manufacturing
Open in API
Filings indexed 1,039 across all filing types
Latest filing 2012-01-10 Regulatory Filings
Country US United States of America
Listing US ARWR

About ARROWHEAD PHARMACEUTICALS, INC.

https://arrowheadpharma.com/

Arrowhead Pharmaceuticals, Inc. is a biotechnology company that develops medicines to treat intractable diseases by silencing the genes that cause them. The company utilizes its proprietary RNA interference (RNAi) platform to create therapies that target disease pathways previously considered 'undruggable.' Arrowhead's development pipeline is focused on a broad range of therapeutic areas, including cardiometabolic, pulmonary, neuromuscular, and liver diseases. The company advances a portfolio of clinical-stage candidates designed to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2012
Regulatory Filings Classification · 95% confidence The document is a response letter from Arrowhead Research Corporation to the SEC's Division of Corporation Finance regarding comments on the company's Form S-3 registration statements. It addresses specific SEC comments and amendments to the registration statements. The document is a correspondence related to regulatory filings and amendments, not a financial report, earnings release, or other specific report types. It is also relatively short (2822 characters) and serves as a regulatory communication rather than a report itself. Therefore, it fits best under Regulatory Filings (RNS).
2012-01-10 English
AMENDMENT NO. 1 TO THE FORM S-3
Capital/Financing Update Classification · 95% confidence The document is an Amendment No. 1 to Form S-3, which is a registration statement filed with the SEC under the Securities Act of 1933. It is used to register securities for sale to the public, often for capital raising purposes. The text includes details about the securities being registered, selling stockholders, and the terms of the offering. It is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a report publication announcement, but a substantive filing related to securities registration.
2012-01-10 English
AMENDMENT NO. 1 TO FORM S-3
Capital/Financing Update Classification · 95% confidence The document is titled 'Amendment No. 1 to Form S-3' and is a registration statement filed with the SEC under the Securities Act of 1933. It includes detailed information about the registration of shares for sale by selling stockholders, the company's business description, risk factors, and other disclosures typical of a securities registration statement. Form S-3 is a registration form used by companies to register securities for public offering, often for resale by existing shareholders or for capital raising. This document is not an annual report, earnings release, or any other financial report but a capital markets filing related to securities registration. Therefore, it fits best under the category 'Capital/Financing Update' (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is substantial (15,000 characters), and it contains the full registration statement amendment, not just an announcement or notice, so it is not an RPA or RNS. Hence, the classification is CAP with high confidence.
2012-01-10 English
STOCK OPTION DATED 12/22/2011
Director's Dealing
2012-01-06 English
AMENDMENT NO.1 TO FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is an amendment to a Form 8-K filing, specifically an 8-K/A, which is a Current Report filed with the SEC. It amends a previous 8-K to provide financial statements and pro forma financial statements related to an acquisition. The document includes audited financial statements of the acquired business and unaudited pro forma financials. The presence of financial statements related to an acquisition and the nature of the filing as a Current Report amendment indicates this is a Capital/Financing Update (CAP) rather than a full Annual Report or standalone Audit Report. The document is relatively short (3714 characters) and is focused on acquisition-related financial disclosures, consistent with a Capital/Financing Update filing.
2011-12-30 English
PRELIMINARY PROXY STATEMENT
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Preliminary Proxy Statement filed under Schedule 14A with the SEC, related to the Annual Meeting of Stockholders of Arrowhead Research Corporation. It includes detailed information about the meeting agenda, director nominations, voting procedures, and other shareholder meeting materials. The presence of proxy solicitation details and the focus on shareholder voting matters clearly identify this as proxy solicitation material. According to the filing definitions, such materials are classified as Proxy Solicitation & Information Statement (PSI). The document length and content confirm it is the statement itself, not just an announcement or notice.
2011-12-30 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.